| 产品编号 | bsm-41414M |
| 英文名称 | Mouse Anti-SARS-CoV-2 (2019-nCoV) Nucleocapsid antibody |
| 中文名称 | SARS冠状病毒2核衣壳蛋白单克隆抗体 |
| 别 名 | SARS-CoV-2 Nucleocapsid Protein; SARS-CoV-2 NP; nucleocapsid protein [Severe acute respiratory syndrome coronavirus 2]; novel coronavirus N Protein; novel coronavirus Nucleocapsid Protein; 2019-nCoV Nucleoprotein; 2019-nCoV N; 2019nCoV N; 2019-nCoV N Protein; 2019 ncov N Protein; 2019-nCoV nucleocapsid protein. |
 |
Specific References (5) | bsm-41414M has been referenced in 5 publications.
[IF=7.344] Lassaunière, Ria. et al. Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2. Npj Vaccines. 2021 Dec;6(1):1-13 ELISA ; Mouse.
[IF=5.897] Larry L. Luchsinger. et al. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients. J Clin Microbiol. 2020 Nov;58(12):e02005-20 ELISA ; Human.
[IF=3.752] Anders Frische. et al. Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay. PLOS ONE. 2022 Jul;17(7):e0272298 ELISA ; Monkey.
[IF=3.09] Nesbitt, Daniel J.. et al. Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats. Bmc Infect Dis. 2021 Dec;21(1):1-9 ELISA ; Human.
[IF=2.74] Daniel K. Jin. et al. Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”. Plos One. 2021 Apr;16(4):e0250319 ELISA ;
|
| 抗体来源 | Mouse |
| 克隆类型 | Monoclonal |
| 克 隆 号 | 7E1B |
| 交叉反应 | SARS-CoV-2 |
| 产品应用 | WB=1:500-2000,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 46kDa |
| 性 状 | Liquid |
| 浓 度 | ≥1 mg/ml |
| 免 疫 原 | Recombinant SARS-CoV-2 Nucleocapsid Protei: full length |
| 亚 型 | IgG2b |
| 纯化方法 | affinity purified by Protein G |
| 缓 冲 液 | 0.01M PBS (pH7.4) with 0.02% Proclin300. |
| 保存条件 | Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antib |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. Coronavirus nucleoproteins localize to the cytoplasm and the nucleolus, a subnuclear structure, in both virus-infected primary cells and in cells transfected with plasmids that express N protein. Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. During virion assembly, N protein binds to viral RNA and leads to formation of the helical nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. Because of the conservation of N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool. SWISS: P0DTC9 Gene ID: 43740575 |
| 产品图片 |
Sample:
Lane 1: SARS-CoV-2 N protein(Cat# bs-41408P) at 50ng
Lane 2: SARS-CoV-2 N protein(Cat# bs-41408P) at 25ng
Lane 3: SARS-CoV-2 N protein(Cat# bs-41408P) at 5ng
Lane 4: SARS-CoV-2 N protein(Cat# bs-41408P) at 2ng
Lane 5: SARS-CoV-2 N protein(Cat# bs-41408P) at 1ng
Lane 6:SARS-CoV-2 N protein(Cat# bs-41408P) at 0.5ng
Primary: Anti- SARS-CoV-2 N protein (bs-41414M) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Mouse IgG at 1/20000 dilution
Predicted band size: 46 kD
Observed band size: 46 kD
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
